Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1993-05-19
1995-05-30
Nucker, Christine M.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
514 50, 514885, A61K 3820, A01N 4348
Patent
active
054199000
ABSTRACT:
A method for activating a mammalian immune system entails a series of continuous IL-2 infusions that are effected intermittently over an extended period. For example, IL-2 can be administered continuously for a period that is on the order of 5 days in length, and successive infusions of this nature can be separated by a period of at least 4 weeks. Sustained beneficial effects, including elevated CD4 cell counts, restoration of lymphocyte function and an increase in the number of IL-2 receptors, are achieved with such intermittent IL-2 therapy, which can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha.
REFERENCES:
patent: 4866157 (1989-09-01), Durette
patent: 4908433 (1990-03-01), Mertelsmann et al.
patent: 5026687 (1991-06-01), Yarchoan et al.
Stein et al, J. Infect. Dis 165: 352-363, 1993.
Schwartz et al, J. Acquir Immune Defic Syndr 4(1): 11-23, 1991 (abstract only provided).
Schwartz et al, Biotherapy 2: 119-136, 1990.
Oyazu et al, PNAS 87: 2379-2383, 1990.
Matory et al, Journal of Biological Response Modifiers 4: 377-390, 1985.
Fauser A. A., J. of Cellular Biochemistry 45: 353-358, 1991.
Genzyme Catalog, Cytokine Research Products 1991 pp. 19 & 20.
H. Teppler, et al., J. Infect. Dis. 167: 291-298 (1993).
H. Teppler, et al., J. Exp. Med. 177: 483-492 (1993).
S. A. Rosenberg et al, J. Natl Cancer Inst. 85(8): 622-632 (1993).
Lane, et al., J. Biol. Response Mos. 3: 512-516 (1984).
West, "Lymphokine-Activated Killer Lymphocytes: Biotherapeutice Clinical Trials," Imm. Ser. 48: 79-92 (1989).
Schwartz et al., "Safety and Effects of Interleukin-2 Plus Zidovudine in Asymptomatic Individuals Infected with Human Immunodeficiency Virus," J. Acq. Imm. Def. Synd. 4(1): 11-23 (1991).
Kovacs Joseph A.
Lane H. Clifford
Krsek-Staples Julie
Nucker Christine M.
The United States of America as represented by the Department of
LandOfFree
Immunologic enhancement with intermittent interleukin-2 therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunologic enhancement with intermittent interleukin-2 therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunologic enhancement with intermittent interleukin-2 therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-359930